Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8189066 | 0.85 | SOS1 (0.53) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL1200588 | 0.83 | CA1 (0.53) | CA12CA1CA2CA9HTR6 | |
| SCHEMBL3442045 | 0.82 | CA1 (0.56) | CA12CA1CA2CA9CA3 | |
| SCHEMBL3541639 | 0.82 | LMNA (0.58) | CA12CA1CA2CA9HTR6 | |
| SCHEMBL16884985 | 0.82 | CA12 (0.51) | CA12CA1CA2CA9HTR6 | |
| SCHEMBL28327825 | 0.80 | NLRP3 (0.45) | ALDH1A1MAPT | |
| SCHEMBL8959071 | 0.80 | CA2 (0.54) | CA12CA1CA2CA9HTR6 | |
| SCHEMBL27933104 | 0.80 | CA12 (0.50) | CA12CA1CA2CA9HTR6 | |
| SCHEMBL27751149 | 0.79 | CA12 (0.61) | CA12CA1CA2CA9LARS1 | |
| SCHEMBL28104760 | 0.79 | CA12 (0.50) | CA12CA1CA2CA9LARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2461683-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2012-06-13 | — | — | EP | claimed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-4948879-A | Monoazo compounds containing a fiber-reactive group and an oxazolopyridone or oxazinopyridone coupling component | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-08-14 | — | — | US | claimed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| EP-3038618-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2016-07-06 | — | — | EP | disclosed |
| US-9150556-B2 | Benzimidazolone chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| WO-2015031608-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-03-05 | — | — | WO | disclosed |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-0316779-A2 | Pyridone azo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-05-24 | — | — | EP | disclosed |
| US-4559059-A | REACTIVE DYES BONDED TO POLYMER | CIBA-GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
| US-4553975-A | REACTING A DYE WITH COPOLYMER GEL | CIBA GEIGY CORPORATION (US) | 1985-11-19 | — | — | US | disclosed |
| US-4468229-A | Tinted contact lenses and a method for their preparation with reactive dyes | CIBA-GEIGY CORPORATION (US) | 1984-08-28 | — | — | US | disclosed |
| US-4314812-A | Two-phase printing process for preparing conversion articles and discharge resist prints | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-02-09 | — | — | US | disclosed |
| US-4314811-A | Two-phase printing process for preparing conversion articles and discharge resist prints | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-02-09 | — | — | US | disclosed |
| EP-0030786-A2 | Textile colouration process and textiles coloured thereby | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-06-24 | — | — | EP | disclosed |
| US-4092101-A | Process for fixing prints with reactive dyestuffs on textile materials of native or regenerated cellulose and mixtures thereof with synthetic fibers | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233152-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | CA12 4254/4885CA1 3109/4885CA2 1946/4885 |
| US-20100240702-A1 | Benzimidazolone Chymase Inhibitors | CMA1, SERPINB1, CPA3 | CA12 2383/4885CA1 3632/4885CA2 743/4885 |
| US-20180127369-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | CA12 4254/4885CA1 3109/4885CA2 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.